Are there any drug interactions between phentermine and apixaban (Eliquis) in a patient with a history of pulmonary embolism?

No Clinically Significant Drug Interaction Between Phentermine and Apixaban (Eliquis)

There is no documented pharmacokinetic or pharmacodynamic drug interaction between phentermine and apixaban (Eliquis) in patients with a history of pulmonary embolism. These medications can be used together safely with appropriate monitoring.

Mechanism Analysis

Phentermine Metabolism and Interactions

Phentermine is a sympathomimetic amine used for weight management that does not significantly interact with the cytochrome P450 system or P-glycoprotein (P-gp) pathways 1. The FDA labeling for phentermine does not list anticoagulants as contraindicated or requiring dose adjustment 1.

Apixaban Metabolism and Interaction Profile

Apixaban is metabolized primarily through CYP3A4 (approximately 25%) and is a substrate of P-gp 2, 3. Clinically significant interactions occur primarily with:

• Combined strong CYP3A4 AND P-gp inhibitors (e.g., ketoconazole, ritonavir) - requiring dose reduction 2
• Combined strong CYP3A4 AND P-gp inducers (e.g., rifampin, phenytoin) - requiring avoidance 2

Phentermine does not function as a CYP3A4 or P-gp modulator, so it does not affect apixaban exposure 4, 5, 3.

Clinical Considerations for This Patient

Cardiovascular Monitoring with Phentermine

While there is no interaction with apixaban, phentermine carries important cardiovascular warnings that require attention in a patient with PE history 6, 1:

• History of cardiovascular disease is a contraindication to phentermine 1
• Monitor blood pressure and heart rate, as phentermine can cause modest increases 6
• The 2022 AGA guidelines recommend avoiding phentermine-containing products in patients with cardiovascular disease 6

PE-Specific Concerns

For your patient with PE history:

1. Assess PE timing and provocation: If the PE was unprovoked or >6 months ago, indefinite anticoagulation is typically recommended 7

2. Verify appropriate apixaban dosing:

   • Acute PE treatment: 10 mg twice daily for 7 days, then 5 mg twice daily 2
   • Extended prophylaxis (after ≥6 months): Consider reduced dose 2.5 mg twice daily 8, 7

3. Evaluate cardiovascular status: If the PE caused right ventricular dysfunction or the patient has residual cardiopulmonary compromise, phentermine may be contraindicated regardless of drug interactions 6, 1

Practical Recommendation

You can prescribe phentermine and apixaban together IF:

• The PE is resolved without residual cardiovascular impairment
• Blood pressure is controlled (<140/90 mmHg)
• No history of coronary artery disease, arrhythmias, or heart failure 1
• Patient understands the need for blood pressure monitoring 6

Monitor:

• Blood pressure and heart rate every 2-4 weeks initially 6
• Signs of bleeding (standard for any anticoagulated patient)
• PE recurrence symptoms (dyspnea, chest pain, leg swelling) 1

Common Pitfall to Avoid

Do not confuse the cardiovascular contraindications of phentermine with drug-drug interactions. The concern is phentermine's sympathomimetic effects on the cardiovascular system, not a pharmacokinetic interaction with apixaban 6, 1. The decision to use phentermine depends on the patient's current cardiovascular status, not the concurrent use of anticoagulation.